Title: Interprotein
and LegoChem Sign Collaboration Agreement to Develop VEGF Inhibitor to Treat
Solid Tumors Publication: Interprotein website Date: 30 Sep 2010 URL: link
to website
Summary
Interprotein Corporation and LegoChem
Biosciences, Inc. announced that they have signed a collaboration agreement on
VEGF inhibitor programme for further optimization and the development of novel,
orally active drugs to replace current anti-VEGF antibody therapies for the
treatment of various solid tumors by suppressing tumor angiogenesis. About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).
|
|
IP : 106.243.208.*** 
|
